Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Target Recruit Count
- 43
- Registration Number
- NCT06492629
- Locations
- 🇨🇳
Department of Medical Oncology, Beijing, Beijing, China
GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Nasopharyngeal Carcinoma
- Interventions
- Drug: GP Regimen, Nimotuzumab, Sintilimab
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 20
- Registration Number
- NCT06490341
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Phase 2
Active, not recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 40
- Registration Number
- NCT06490107
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy
Phase 2
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: LTC004+Toripalimab
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 10
- Registration Number
- NCT06490068
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-16
- Target Recruit Count
- 40
- Registration Number
- NCT06490081
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases
Phase 2
Not yet recruiting
- Conditions
- Adenocarcinoma of Lung Metastatic to Brain
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 27
- Registration Number
- NCT06483672
Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery
Recruiting
- Conditions
- Lung Cancer
- Interventions
- Other: Sublobar resectionOther: Lobectomy
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 20000
- Registration Number
- NCT06483698
- Locations
- 🇨🇳
Shugeng Gao, Beijing, Beijing, China
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
Active, not recruiting
- Conditions
- Breast Cancer Stage IV
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Target Recruit Count
- 480
- Registration Number
- NCT06481553
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
Phase 3
Recruiting
- Conditions
- Stereotactic RadiotherapySmall-cell Lung CancerWhole Brain RadiotherpayHippocampal-avoidanceBrain MetastasesSRS
- Interventions
- Combination Product: Experimental group (SRS/SRT/Hypo-RT)Radiation: Controled group (HA-WBRT)
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Target Recruit Count
- 340
- Registration Number
- NCT06457906
- Locations
- 🇨🇳
Nan Bi, Beijing, Beijing, China
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Target Recruit Count
- 91
- Registration Number
- NCT06452433
© Copyright 2025. All Rights Reserved by MedPath